Gossamer Bio Shareholders May Pursue Class Action Over Alleged Misleading Statements
Gossamer Bio, Inc. (NASDAQ: GOSS) shareholders are being alerted about a potential class action lawsuit due to alleged misleading statements regarding the Phase 3 PROSERA study results. The stock price dropped over 80% following the announcement of the study's failure to meet its primary endpoint. The class period spans from June 16, 2025, to February 20, 2026.
Tickers: $GOSS
Topics: class action misleading statements Phase 3 trial failure securities fraud stock price drop